Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC.

J Clin Oncol. 2012 Oct 1;30(28):3525-32. Epub 2012 Aug 27.

PMID:
22927533
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC.

J Natl Cancer Inst. 2006 Sep 6;98(17):1193-203.

PMID:
16954472
[PubMed - indexed for MEDLINE]
Free Article
3.

Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.

Kobayashi C, Monforte-Munoz HL, Gerbing RB, Stram DO, Matthay KK, Lukens JN, Seeger RC, Shimada H.

Cancer. 2005 Jan 1;103(1):174-80.

PMID:
15549714
[PubMed - indexed for MEDLINE]
Free Article
4.

Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC.

J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6.

PMID:
7674334
[PubMed - indexed for MEDLINE]
5.

Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.

Cancer. 2001 Nov 15;92(10):2699-708.

PMID:
11745206
[PubMed - indexed for MEDLINE]
6.

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.

Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK.

J Clin Oncol. 2005 Sep 20;23(27):6474-80. Epub 2005 Aug 22.

PMID:
16116154
[PubMed - indexed for MEDLINE]
Free Article
7.

Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.

J Clin Oncol. 2005 Sep 20;23(27):6466-73. Epub 2005 Aug 22.

PMID:
16116152
[PubMed - indexed for MEDLINE]
Free Article
8.

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J, Sommelet D.

J Clin Oncol. 1997 Mar;15(3):1171-82.

PMID:
9060561
[PubMed - indexed for MEDLINE]
9.

Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.

Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL; International Neuroblastoma Risk Group.

J Clin Oncol. 2009 Jan 20;27(3):365-70. doi: 10.1200/JCO.2008.17.9184. Epub 2008 Dec 1.

PMID:
19047282
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Occurrence and prognostic impact of selected factors in neuroblastoma in children].

Wieczorek A, Balwierz W.

Przegl Lek. 2010;67(6):393-8. Polish.

PMID:
21344768
[PubMed - indexed for MEDLINE]
11.

Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M.

Pediatr Dev Pathol. 2011 Mar-Apr;14(2):87-92. doi: 10.2350/08-12-0579.1. Epub 2011 Feb 2.

PMID:
21288077
[PubMed - indexed for MEDLINE]
12.

Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.

Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK.

J Clin Oncol. 2011 Nov 20;29(33):4358-64. doi: 10.1200/JCO.2011.35.9570. Epub 2011 Oct 3.

PMID:
21969516
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

High genomic instability predicts survival in metastatic high-risk neuroblastoma.

Stigliani S, Coco S, Moretti S, Oberthuer A, Fischer M, Theissen J, Gallo F, Garavent A, Berthold F, Bonassi S, Tonini GP, Scaruffi P.

Neoplasia. 2012 Sep;14(9):823-32.

PMID:
23019414
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.

PMID:
23091029
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, Díaz de Ståhl T, Hedborg F.

BMC Cancer. 2013 May 9;13:231. doi: 10.1186/1471-2407-13-231.

PMID:
23656755
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.

Raschellà G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, Tonini GP, De Bernardi B, Calabretta B.

Cancer Res. 1999 Jul 15;59(14):3365-8.

PMID:
10416595
[PubMed - indexed for MEDLINE]
Free Article
17.

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.

Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC.

J Clin Oncol. 2005 Dec 1;23(34):8819-27.

PMID:
16314642
[PubMed - indexed for MEDLINE]
Free Article
18.

Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.

Li P, Gao Y, Ji Z, Zhang X, Xu Q, Li G, Guo Z, Zheng B, Guo X.

J Pediatr Surg. 2004 Oct;39(10):1512-9.

PMID:
15486896
[PubMed - indexed for MEDLINE]
19.

Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.

Terui E, Matsunaga T, Yoshida H, Kouchi K, Kuroda H, Hishiki T, Saito T, Yamada S, Shirasawa H, Ohnuma N.

Clin Cancer Res. 2005 May 1;11(9):3280-7.

PMID:
15867224
[PubMed - indexed for MEDLINE]
Free Article
20.

Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.

Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE.

Clin Cancer Res. 2006 Oct 1;12(19):5693-7.

PMID:
17020972
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk